All Blogs
May 22, 2025
FDA Clears Fujirebio’s Lumipulse® G Plasma Test for Detecting Alzheimer’s-Linked Amyloid Pathology; Stryker Gains FDA Clearance for OptaBlate® BVN System to Treat Chronic Low Back Pain; Abbott Unveils Clinical Evidence Linking Libre® CGM to Reduced Cardiovascular Events in Diabetes; GE HealthCare Launches AI-Based CleaRecon DL for Enhanced 3D Reconstruction in Interventional Suites; Philips Advances Cardiac Care with Launch of RADIQAL Clinical Study and Real-Time 3D Intracardiac Imaging Catheter in Europe
Fujirebio Received FDA Clearance for Innovative Lumipulse® G Plasma Biomarker Test, Marking Major Advancement in Identifying Amyloid Pathology Linked to Alzheimer’s Disease On May 16, 2025, Fujirebio announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its Lumipulse® G pT...
Read More...
May 21, 2025
Unveiling Lysosomal Storage Disorders: Exploring Rare Diseases Impacting Millions Worldwide
Lysosomal Storage Disorders, or LSDs, are rare genetic conditions that may not make headlines, but they affect thousands worldwide, often with life-changing consequences. LSDs happen when the body’s lysosomes, tiny cellular recycling centers, fail to break down waste materials due to missing or faulty enzymes. This...
Read More...
May 20, 2025
Incyte’s ZYNYZ Approved as First-Line Treatment for Advanced Anal Cancer; Amneal Gets FDA Nod for BREKIYA for Migraines; FDA Accepts Travere’s sNDA for FILSPARI in FSGS; AbbVie’s EMRELIS Approved for Advanced NSCLC With High c-Met; Merck’s WELIREG Approved for Advanced PPGL in Patients 12+
Incyte’s ZYNYZ Approved by FDA as First-Line Treatment for Advanced Anal Cancer The FDA approved ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor developed by Incyte, for the treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The approval incl...
Read More...
May 19, 2025
7 Emerging Spinal Muscular Atrophy Therapies Offering Hope for Patients
The approval of three spinal muscular atrophy therapies—SPINRAZA (Ionis/Biogen), EVRYSDI (Roche), and the groundbreaking gene therapy ZOLGENSMA (Novartis) has significantly advanced treatment options for a condition that previously had limited solutions. These spinal muscular atrophy (SMA) therapies offer patients ...
Read More...
May 16, 2025
J&J Enters gMG Arena with IMAAVY Approval, Challenging AstraZeneca, Argenx, and UCB
The FDA has approved Johnson & Johnson’s anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis (gMG). This myasthenia gravis drug will be marketed under the name IMAAVY. Although J&J isn’t the first to receive FDA approval for an FcRn-blocking antibody in this indication, the c...
Read More...
May 15, 2025
Glucotrack Secures Ethical Approval for Extended Clinical Trial of Continuous Blood Glucose Monitor; GE HealthCare Announces FDA Approval for Pediatric Use of Optison and Launches New Ultra-premium 1.5T MRI System; Envoy Medical Advances to Final Stage Following Clinical Milestone; SeaStar Medical Hits Interim Enrollment Goal in NEUTRALIZE-AKI Trial; BD Unveils New Cell Analyzer Integrating Spectral and Real-Time Imaging Innovations
Glucotrack Announced Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor On May 13, 2025, Glucotrack, Inc., a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it received ethical app...
Read More...
May 14, 2025
Generative AI in Drug Discovery: Applications and Market Impact
The pharmaceutical industry stands at a crossroads, where innovation is no longer a luxury but a necessity. The AI in the drug discovery market is at the forefront of this transformation, driven by the remarkable capabilities of generative AI. This technology, which creates novel solutions by learning from vast dat...
Read More...
May 13, 2025
Eli Lilly’s ZEPBOUND Surpasses WEGOVY in SURMOUNT-5 Trial; Verastem Oncology Secures FDA Approval for AVMAPKI + FAKZYNJA in KRAS-Mutant Ovarian Cancer; Thermosome Gains Orphan Drug Designation for THE001; Beam Therapeutics Receives RMAT Status for BEAM-302 in AATD; Capsida Biotherapeutics Gets IND Clearance for STXBP1 Gene Therapy
Eli Lilly’s ZEPBOUND Outperforms WEGOVY in SURMOUNT-5 Trial Eli Lilly and Company released detailed results from the Phase IIIb SURMOUNT-5 clinical trial, showing that ZEPBOUND (tirzepatide) significantly outperformed WEGOVY (semaglutide) in weight loss among adults with obesity or overweight and at least one we...
Read More...
May 12, 2025
Spinal Muscular Dystrophy Treatment: A Deep Dive into Current Therapies and Future Prospects
Spinal muscular atrophy (SMA) is the second most prevalent autosomal recessive disorder, with a carrier frequency of approximately 1 in 40 to 50 individuals and an estimated occurrence of 1 in 10,000 live births. The majority of SMA cases are caused by the deletion of a portion of the SMN1 gene, which impairs the p...
Read More...
May 09, 2025
Congenital Adrenal Hyperplasia Treatment in Transition: Innovations, Setbacks, and Strategic Shifts Shaping the Market
Congenital Adrenal Hyperplasia (CAH) is a group of inherited genetic disorders that affect adrenal gland function, most commonly caused by a deficiency in the enzyme 21-hydroxylase. This enzyme deficiency disrupts the production of cortisol and often aldosterone, leading to hormonal imbalances and excess androgen p...
Read More...